Literature DB >> 30919223

Symptoms of and Palliative Treatment for Unresectable Skin Cancer.

Hiroyuki Goto1, Yoshio Kiyohara2, Masahisa Shindo3, Osamu Yamamoto4.   

Abstract

OPINION STATEMENT: The symptom prevalence in patients with advanced cancer depends on the type of primary cancer, and the palliative treatment varies according to the nature of the primary cancer. Palliative treatment for unresectable skin cancer has not been fully discussed. Patients with unresectable skin cancer sometimes show the primary lesion in the skin and metastases to the lung, skin, liver, and bone. Pain, anorexia, and dyspnea commonly occur in such patients, and bleeding, exudate, and offensive odor are characteristically observed. For the last three symptoms, surgery and radiation are effective therapeutic options, and cryotherapy, Mohs' chemosurgery, electrochemotherapy, and some topical ointments and dressing materials are also additional options. For pain due to bone metastasis, pharmacotherapy with opioid and/or non-opioid agents is the most basic treatment, and radiation and bisphosphonate therapies are other options. For dyspnea, which is an intractable and uncomfortable symptom, morphine and oxygen play a leading role in treatment. Red blood cell transfusions may be effective for some patients with dyspnea induced by anemia. Nutritional supports and pharmacotherapy are therapeutic options for anorexia. As nutritional supports, enteral nutrition is better than parenteral nutrition. There is some evidence of progestins and corticosteroids having supportive effects for anorexia. Dermatologic oncologists should be skilled with symptom managements to maintain the quality of life in patients with unresectable skin cancer and their families.

Entities:  

Keywords:  Metastasis; Palliative care; Quality of life; Skin cancer

Year:  2019        PMID: 30919223     DOI: 10.1007/s11864-019-0626-5

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  57 in total

Review 1.  Strategies to manage the adverse effects of oral morphine: an evidence-based report.

Authors:  N Cherny; C Ripamonti; J Pereira; C Davis; M Fallon; H McQuay; S Mercadante; G Pasternak; V Ventafridda
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

Review 2.  Cryosurgery: unapproved uses, dosages, or indications.

Authors:  Rodney Dawber
Journal:  Clin Dermatol       Date:  2002 Sep-Oct       Impact factor: 3.541

Review 3.  Symptom prevalence in patients with incurable cancer: a systematic review.

Authors:  Saskia C C M Teunissen; Wendy Wesker; Cas Kruitwagen; Hanneke C J M de Haes; Emile E Voest; Alexander de Graeff
Journal:  J Pain Symptom Manage       Date:  2007-05-23       Impact factor: 3.612

Review 4.  Systematic review of the treatment of cancer-associated anorexia and weight loss.

Authors:  Tugba Yavuzsen; Mellar P Davis; Declan Walsh; Susan LeGrand; Ruth Lagman
Journal:  J Clin Oncol       Date:  2005-11-20       Impact factor: 44.544

5.  Contributing factors to physical symptoms in terminally-ill cancer patients.

Authors:  T Morita; J Tsunoda; S Inoue; S Chihara
Journal:  J Pain Symptom Manage       Date:  1999-11       Impact factor: 3.612

Review 6.  Cancer anorexia-cachexia syndrome: current issues in research and management.

Authors:  Akio Inui
Journal:  CA Cancer J Clin       Date:  2002 Mar-Apr       Impact factor: 508.702

7.  Symptom prevalence and control during cancer patients' last days of life.

Authors:  V Ventafridda; C Ripamonti; F De Conno; M Tamburini; B R Cassileth
Journal:  J Palliat Care       Date:  1990       Impact factor: 2.250

Review 8.  Terminal care: the last weeks of life.

Authors:  William M Plonk; Robert M Arnold
Journal:  J Palliat Med       Date:  2005-10       Impact factor: 2.947

9.  Impaired communication capacity and agitated delirium in the final week of terminally ill cancer patients: prevalence and identification of research focus.

Authors:  Tatsuya Morita; You Tei; Satoshi Inoue
Journal:  J Pain Symptom Manage       Date:  2003-09       Impact factor: 3.612

Review 10.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

Authors:  M Aapro; P A Abrahamsson; J J Body; R E Coleman; R Colomer; L Costa; L Crinò; L Dirix; M Gnant; J Gralow; P Hadji; G N Hortobagyi; W Jonat; A Lipton; A Monnier; A H G Paterson; R Rizzoli; F Saad; B Thürlimann
Journal:  Ann Oncol       Date:  2007-09-28       Impact factor: 32.976

View more
  3 in total

Review 1.  Treatment of keratinocyte carcinoma in elderly patients - a review of the current literature.

Authors:  A J G Leus; M Frie; M S Haisma; J B Terra; B E C Plaat; R J H M Steenbakkers; G B Halmos; E Rácz
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-03-30       Impact factor: 6.166

2.  Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases.

Authors:  Gao Zhang; Hu Gong; Hanqiao Xu
Journal:  Comput Math Methods Med       Date:  2021-12-13       Impact factor: 2.238

3.  A Cross-Sectional Survey of Knowledge of Skin Cancer in Saudi Arabia.

Authors:  Hend M Al-Atif
Journal:  Dermatol Pract Concept       Date:  2021-05-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.